Company Overview

Skye Bioscience, Inc. is a U.S.-based clinical-stage biotechnology company focused on the development of therapeutics targeting metabolic, inflammatory, and fibrotic diseases through modulation of the endocannabinoid system and related pathways. The company operates within the biotechnology and pharmaceutical industries, with its primary emphasis on obesity, metabolic health, and associated chronic conditions. Its core value proposition centers on developing differentiated biologic and small-molecule therapies intended to improve efficacy and tolerability compared with existing treatments in rapidly growing metabolic disease markets.

The company historically explored cannabinoid-derived pharmaceutical programs in ophthalmology and other indications before repositioning its strategy toward obesity and metabolic disorders. A major component of this transition involved advancing nimacimab, a monoclonal antibody targeting peripheral CB1 receptors, as a potential treatment for obesity and related metabolic conditions. Skye Bioscience has positioned itself within the broader metabolic therapeutics sector by pursuing non-central nervous system cannabinoid pathway modulation, which the company believes may reduce psychiatric side effects historically associated with earlier CB1-targeting drugs.

Business Operations

Skye Bioscience primarily operates as a single-segment clinical-stage biotechnology business focused on drug research, development, and clinical advancement rather than commercial product sales. Revenue generation has historically been limited, with the company primarily funded through equity offerings, strategic financing activities, and capital market transactions disclosed in SEC filings. Its operational focus includes clinical development, regulatory engagement, intellectual property management, and external manufacturing and research partnerships supporting therapeutic candidates.

The company’s principal asset is nimacimab, which was obtained through the acquisition of rights associated with Bird Rock Bio, Inc. Skye Bioscience relies on contract research organizations, clinical trial operators, and manufacturing partners to support development activities in the United States and internationally. While the company does not currently maintain large-scale commercial infrastructure, it controls intellectual property and development rights associated with its lead metabolic disease programs and continues to evaluate opportunities for strategic collaborations and portfolio expansion.

Strategic Position & Investments

Skye Bioscience’s strategic direction is centered on expanding its presence in the obesity and metabolic disease therapeutics market, an area that has attracted significant pharmaceutical industry investment due to rising global obesity prevalence and demand for next-generation treatments. The company has focused on advancing clinical development for nimacimab both as a standalone therapy and potentially in combination approaches. Its strategy emphasizes peripheral CB1 inhibition, differentiating its platform from earlier cannabinoid receptor therapies associated with central nervous system adverse effects.

A notable strategic transaction involved the acquisition and integration of Bird Rock Bio, Inc., which strengthened Skye Bioscience’s metabolic disease pipeline and intellectual property portfolio. The company has also pursued financing initiatives intended to support clinical trials and operational expansion. Emerging areas of interest include therapies targeting obesity-related inflammation, insulin resistance, and broader cardiometabolic disorders. Data regarding future commercial partnerships or large-scale licensing arrangements remains inconclusive based on available public sources.

Geographic Footprint

Skye Bioscience is headquartered in San Diego, California, and primarily conducts operations within the United States. Its clinical development activities, regulatory engagement, and investor relations efforts are largely U.S.-focused, though the company may utilize international clinical research and manufacturing partners depending on trial requirements and supply-chain considerations.

The company’s operational influence extends indirectly into international markets through outsourced research relationships, intellectual property protections, and participation in globally relevant metabolic disease therapeutic development. While Skye Bioscience does not currently report a broad multinational commercial footprint comparable to large pharmaceutical companies, its therapeutic focus targets global obesity and metabolic disease markets across North America, Europe, and other regions with increasing demand for innovative metabolic treatments.

Leadership & Governance

Skye Bioscience is led by a management team with experience in biotechnology development, capital markets, and pharmaceutical strategy. Leadership has emphasized disciplined clinical execution, metabolic disease innovation, and long-term value creation through differentiated therapeutic mechanisms. The company operates under a publicly traded governance structure and files regular disclosures through the U.S. Securities and Exchange Commission (SEC).

Key executives and leadership figures include:

• Punit Dhillon – Executive Chair
• Khurem Farooq – Chief Executive Officer
• Gregory J. Borgen – Chief Financial Officer
• Praveen Tyle, Ph.D. – President, Research and Development
• Karen A. Dawes – Senior Vice President, Clinical Development

The company’s leadership strategy has focused on advancing clinical-stage assets efficiently while positioning Skye Bioscience within the competitive obesity and metabolic therapeutics landscape. Public disclosures indicate continued emphasis on capital discipline, strategic clinical milestones, and scientific differentiation in cannabinoid-related metabolic therapies.